Imunon (IMNN) Competitors

Imunon (NASDAQ:IMNN) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Is IMNN or ASRT more profitable?

Imunon has a net margin of 0.00% compared to Assertio's net margin of -36.97%. Assertio's return on equity of -38.19% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-405.07%	-158.41%
Assertio	-36.97%	-38.19%	-15.45%

Do insiders & institutionals hold more shares of IMNN or ASRT?

4.5% of Imunon shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 6.0% of Imunon shares are held by company insiders. Comparatively, 4.0% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has better earnings and valuation, IMNN or ASRT?

Imunon has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	$500K	32.21	-$18.62M	-$12.95	-0.51
Assertio	$124.96M	0.63	-$21.58M	-$0.45	-1.82

Does the media refer more to IMNN or ASRT?

In the previous week, Assertio had 3 more articles in the media than Imunon. MarketBeat recorded 13 mentions for Assertio and 10 mentions for Imunon. Imunon's average media sentiment score of 0.28 beat Assertio's score of -0.18 indicating that Imunon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts recommend IMNN or ASRT?

Imunon currently has a consensus price target of $232.50, suggesting a potential upside of 3,422.73%. Assertio has a consensus price target of $2.38, suggesting a potential upside of 190.24%. Given Imunon's higher probable upside, equities research analysts plainly believe Imunon is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Assertio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, IMNN or ASRT?

Imunon has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Assertio has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Summary

Imunon beats Assertio on 9 of the 17 factors compared between the two stocks.